12/16
08:07 am
cort
Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism [Yahoo! Finance]
Low
Report
Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism [Yahoo! Finance]
12/16
08:00 am
cort
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
Medium
Report
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
12/12
04:05 pm
cort
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes
Medium
Report
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes
12/11
04:19 pm
cort
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) [Yahoo! Finance]
Medium
Report
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) [Yahoo! Finance]
12/11
04:05 pm
cort
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
Low
Report
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
12/3
08:23 am
cort
Corcept Therapeutics (NASDAQ:CORT) shareholders have earned a 34% CAGR over the last five years [Yahoo! Finance]
Low
Report
Corcept Therapeutics (NASDAQ:CORT) shareholders have earned a 34% CAGR over the last five years [Yahoo! Finance]
11/29
01:00 pm
cort
Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
Neutral
Report
Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
11/26
12:06 am
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
11/25
11:40 am
cort
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term [Yahoo! Finance]
Low
Report
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term [Yahoo! Finance]
11/22
12:49 pm
cort
Corcept Shares Rise More Than 60% in Three Months: Here's Why [Yahoo! Finance]
Low
Report
Corcept Shares Rise More Than 60% in Three Months: Here's Why [Yahoo! Finance]
11/20
11:12 am
cort
Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet [Yahoo! Finance]
Low
Report
Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet [Yahoo! Finance]
11/20
10:12 am
cort
Corcept (CORT) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]
Medium
Report
Corcept (CORT) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]
11/8
08:56 am
cort
5 Small Drug Stocks to Buy as Trump Gets Re-Elected [Yahoo! Finance]
Medium
Report
5 Small Drug Stocks to Buy as Trump Gets Re-Elected [Yahoo! Finance]
11/5
11:04 am
cort
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out? [Yahoo! Finance]
Medium
Report
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out? [Yahoo! Finance]
11/4
11:43 am
cort
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
Low
Report
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
11/4
11:43 am
cort
Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade [Yahoo! Finance]
Low
Report
Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade [Yahoo! Finance]
11/4
10:47 am
cort
Recent Price Trend in Corcept (CORT) is Your Friend, Here's Why [Yahoo! Finance]
Low
Report
Recent Price Trend in Corcept (CORT) is Your Friend, Here's Why [Yahoo! Finance]
11/1
02:04 pm
cort
Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy? [Yahoo! Finance]
Low
Report
Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy? [Yahoo! Finance]
11/1
08:40 am
cort
Corcept's relacorilant GRADIENT trial misses primary endpoint [Yahoo! Finance]
Low
Report
Corcept's relacorilant GRADIENT trial misses primary endpoint [Yahoo! Finance]
11/1
08:17 am
cort
Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
10/31
11:05 pm
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Medium
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
10/31
08:35 am
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
High
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
10/30
04:05 pm
cort
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update
Low
Report
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update
10/23
04:05 pm
cort
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Low
Report
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
10/18
03:33 pm
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at Sandler O'Neill.
Low
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at Sandler O'Neill.